OCS Oculis Holding AG
USHealthcareAs of 2026-07-10 16:00
Why OCS matters now
Oculis Holding AG (OCS) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.63 with -0.51% on the session and $779.2M in market capitalization; recent performance reads 1-month -59.87% and YTD -43.82%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-29.5M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -12.1%.
The latest indexable market news headline is "Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $38.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.72
P/S
1026.31
EV/EBITDA
-4.84
DCF Value
$1.89
FCF Yield
-12.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-2889.4%
Operating Margin
-16741.0%
Net Margin
-18861.3%
ROE
-57.1%
ROA
-39.1%
ROIC
-42.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-29.5M | $-0.50 |
| Q4 2025 | $0.00 | $-23.3M | $-0.42 |
| FY 2025 | $0.00 | $-94.5M | $-1.81 |
| Q3 2025 | $243.0K | $-16.9M | $-0.32 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$39.40
Target (Median)
$38.00
Target Range
$26.00 - $50.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CH
Exchange
—
Beta
0.13
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.